Tag: Antibody-drug conjugate breakthrough

Home / Antibody-drug conjugate breakthrough

Categories

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cer...
antibody-drug-conjugate-breakthrough

Scan the code